GlassScriptPhysician profile
Catherine P Phillippi
NPI 1578674883
$1,938.76
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $738 · 2020: $30.10 · 2021: $285 · 2022: $165 · 2023: $214 · 2024: $507.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $720.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $720.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofire Diagnostics, LLC | $500.00 | 2019 | |
| Corium, LLC | $362.35 | 2022-2024 | Azstarys |
| Pfizer INC. | $179.78 | 2019-2024 | |
| Sanofi Pasteur INC. | $163.18 | 2021-2024 | |
| Ironshore Pharmaceuticals INC. | $143.02 | 2019-2024 | |
| Tris Pharma INC | $134.22 | 2021-2024 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $110.99 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $106.96 | 2021-2024 | Vaxneuvance, Gardasil 9, Vaxelis |
| Supernus Pharmaceuticals, INC. | $86.17 | 2024 | Qelbree |
| Neos Therapeutics, LP | $43.39 | 2019-2020 | |
| Glaxosmithkline, LLC. | $25.77 | 2019-2021 | |
| Shire North American Group INC | $25.72 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $19.00 | 2019 | |
| Sobi, INC | $14.87 | 2019 | |
| Genentech USA, INC. | $11.76 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $11.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Phillippi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.